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Objective
To assess the beneficial effects of some of the available
therapeutic agents in the management of AIDS-related
Kaposi's sarcoma in a resource limited setting.
Patients/methods
The study was conducted between 2003 and 2007 at
Ahmadu Bello University Teaching Hospital, a tertiary
referral center in Zaria, Nigeria. There were 37 histologi-
cally diagnosed KS. All the cases were HIV-1 antibody pos-
itive by parallel ELISA method (Immunocomb and Genie
II). Complete blood count was carried out by either stand-
ard manual and automated methods (Advia® 60). CD4+ T
lymphocytes enumerated using Dynabeads or Cyflow.
Facilities for KS herpes virus type 8 serological screening
were not available. Other ancillary investigations were
carried out. The modalities of treatment include antiretro-
viral therapy (ART), Chemotherapy and Surgical excision.
Results
During a 5-year period, 37 antiretroviral naïve patients
were recruited into this study. Men were predominantly
affected, with a male to female ratio of 2.3:1. Cutaneous
lesions were the earliest and commonest mode of presen-
tation in all the patients. Visceral involvement could not
be assessed due to lack of appropriate endoscopic biopsy
tools. The mean packed cell volume was 0.28 and a mean
CD4+ T Lymphocyte counts of 262.6-cells/μl of blood.
Eight patients died pre-evaluation to commencement of
any form of therapy due to late hospital presentation
(extensive and progressive disease), nine patients were
lost to follow up after commencement of ART and or
chemotherapy. Five patients who had localized cutaneous
KS lesions were on ART alone. Of the remaining 15 that
had chemotherapy, five had single agent (Vincristine 1.4
mg/m2 every 2 weeks for six cycles) at $12 per cycle and
only one had vinblastine alone, while eight had polyche-
motherapy, (Adriamycin 10 mg/m2, Bleomycin 10 U/m2
and Vincristine 1.4 mg/m2 every 2 weeks for six cycles
except for one who discontinued due to cost) at $89 per
cycle. Complete remission was achieved in two patients
and partial remission in the remaining six patients that
received polychemotherapeutic ABV regimen (partial
remission defined as 50 percent regression in tumor size,
improvement in clinical status and CD4 count) compared
to those who had single agent chemotherapy or ART alone
(no remission was achieved). The last patient was a 9-
year-old girl who was treated with ART and surgical exci-
sion of the localized lesions. Management is hampered by
late hospital presentation, presence of other co-morbid
conditions such as tuberculosis, affordability and availa-
bility of the recommended choice of therapeutic agents in
country where majority of the population subsists on less
than $1 per day.
Conclusion
These finding suggest that ABV regimen remains an effec-
tive treatment option in resource limited settings where
the internationally approved chemotherapeutic agents
such as Paclitaxel, Liposomal doxorubicin and immune
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modulators (alpha interferon) are beyond the reach of the
majority of the population.Page 2 of 2
(page number not for citation purposes)
